Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resistant interleukin-18 (IL-18). By unlocking the potential of IL-18, Simcha is developing its lead program (ST-067) as monotherapy and in combination with potentially several other anticancer agents. ST-067 is currently being studied in a Phase 1/2 clinical trial, in patients with solid tumors and who have progressed on other immunotherapeutic agents. Beyond IL-18, the company’s underlying approach to immune-biology and cytokine engineering has broader potential to support disease-modifying therapeutic options for a range of significant diseases.
View Top Employees from Simcha TherapeuticsWebsite | https://www.simchatx.com/ |
Employees | 13 (10 on RocketReach) |
Technologies |
JavaScript,
HTML,
Twitter
+8 more
(view full list)
|
Industry | Biotechnology Research |
Looking for a particular Simcha Therapeutics employee's phone or email?
Sanuj Ravindran is the CEO of Simcha Therapeutics.
10 people are employed at Simcha Therapeutics.